- $54.51m
- $51.55m
- CA$15.56m
MindWalk Holdings Corp reports results for the quarter ended July 31 - Earnings Summary
Canada's MindWalk Q1 net loss widens on higher sales, marketing expenses
MindWalk Holdings Corp expected to post a loss of 8 cents a share - Earnings Preview
Brief: MindWalk Showcases Reefiq™ For Ai Drug Discovery At AMD Advancing Ai
MindWalk Holdings Corp reports results for the quarter ended April 30 - Earnings Summary
Brief: MindWalk Holdings Corp Q4 Revenue CAD 4.1 Million
Canada's MindWalk Q4 revenue misses estimates
MindWalk Holdings Corp expected to post a loss of 7 cents a share - Earnings Preview
Brief: Mindwalk Holdings May Offer Up To $250 Million Of Securities Over 36 Months - SEC Filing
U.S. RESEARCH ROUNDUP- CME Group, M&T Bank, PNC Financial Services
Canada's MindWalk Q3 revenue rises on US growth
Brief: MindWalk Announces B Cell Llama™, A Nanobody Discovery Platform Designed For The Bispecific And Cell Therapy Era
Brief: Mindwalk Holdings Entered Sales Agreement With Jonestrading Institutional Services To Offer Up To $30 Million Common Shares
Brief: MindWalk Appoints R. Scott Areglado as Chief Financial Officer to Strengthen Financial Leadership and Support Growth Strategy
Brief: MindWalk Appoints Dr. Thomas W. Lynch As Chief Business Officer To Accelerate Commercial Expansion
Brief: MindWalk Advances AI-Designed GLP-1 Program with First-in-Class Dual-Pathway Regimen for Aging and Longevity
Brief: Immunoprecise Rebrands As Mindwalk, Announces Nasdaq Ticker Change To “Hyft”
Brief: Immunoprecise Antibodies Ltd. Divests Netherlands Facilities To AVS Bio
Immunoprecise Antibodies Ltd reports results for the quarter ended April 30 - Earnings Summary